Biotech Values

[Regulardoc]

Sorry for the delay, picnic with the grandkids.

Truly have no idea why B-I has not gone after the DVT indication. If truly "only" a $100 million annual market, and if to be split two or three ways, perhaps they felt it was not worthwhile pursuing.

Another thing about Xarelto approval, as discussed months ago on this board, is that orthopedic surgeons are all over the map in how they provide DVT prophylaxis, and I doubt if the FDA's duration of treatment and basis for approval will be followed by a majority of orthopedic surgeons.